283 results about "Inhibitory peptide" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention belongs to the field of skin care products, and particularly relates to an anti-wrinkle and anti-aging composition as well as a preparation method and application thereof, and the anti-wrinkle and anti-aging composition comprises neurotransmitter inhibition peptide, signal peptide, madecassoside, inositol and glycosylglycerol. The neurotransmitter inhibition type peptide is at least three of acetyl hexapeptide-8, arginine / lysine polypeptide, dipeptide diaminobutyrylbenzylamide diacetate and acetyl octapeptide-3, and the signal type peptide is at least two of palmitoyl pentapeptide-4, decapeptide-4 and acetyl tetrapeptide-9. Compared with the prior art, all the components of the anti-wrinkle and anti-aging composition act on different anti-aging pathways and can be matched with one another from multiple aspects of oxidation resistance, inflammation resistance, moisturizing, cell viability enhancement, wrinkle reduction and the like, a more comprehensive and better anti-aging effect is provided, skin aging is comprehensively resisted, the skin is in a more young state, and the anti-wrinkle and anti-aging composition has the advantages that the anti-wrinkle and anti-aging effects are achieved. And the anti-wrinkle and anti-aging composition is small in irritation and good in stability.

The invention discloses a method for preparing, enriching and separating various egg yolk bioactive peptides through enzymolysis of defatted egg yolk powder and application of the egg yolk bioactive peptides, and belongs to the technical field of egg product processing and bioactive peptides. Egg yolk protein hydrolysate is prepared by adopting a three-step enzymolysis process, adsorption and gradient elution are performed on the egg yolk protein hydrolysate by adopting a macroporous resin chromatographic column, four components including water-1, water-2, 20% ethanol and 80% ethanol are obtained, the water-1 component is common egg yolk peptide, the water-1 component is enriched with osteogenic active peptide, the water-2 component is enriched with ethanol, and the 80% ethanol is enriched with ethanol. The 20% ethanol component enriches antioxidant peptide, and the 80% ethanol component enriches ACE inhibitory peptide. The functional activity of each bioactive peptide component is very strong, and the bioactive peptide component can be used as a high-end functional ingredient. According to the method disclosed by the invention, comprehensive utilization of the degreased yolk powder is realized, enrichment and separation of three active peptides are realized by using one raw material through a step-by-step enzymolysis-directional separation technology, the yield of the active peptides is greatly improved, and the economic benefits of enterprises are improved.

An α-amylase inhibitory peptide. The peptide comprises amino acid sequences of eight adjacent amino acids X1, X2, X3, X4, X5, X6, X7, and X8, wherein each amino acid of the peptide is independently selected from a D-amino acid or an L-amino acid, and at least one of X2, X4, and X6 is W. The peptide has α-amylase inhibitory activity, has the effects of losing weight and lowering blood sugar, and can be used for preparing α-amylase inhibitors, weight-losing drugs, hypoglycemic drugs, or foods, health-care products or drugs for preventing or treating obesity-related diseases.

The invention relates to the technical field of biology, in particular to a DPP-IV inhibitory peptide extracted from buffalo cheese protein hydrolysate and application of the DPP-IV inhibitory peptide. An active component with the molecular weight smaller than 3 kDa is obtained through alkaline protease enzymolysis, ultrafiltration separation and LC-MS / MS identification, and the DPP-IV enzyme inhibitory activity IC50 value of the active component is 12.6 mg / mL. Four new DPP-IV inhibitory peptide fragments are found, are amino acid sequences in a sequence table SEQ ID NO: 1-4, have good DPP-IV inhibitory activity, and have good application prospects in being developed into functional foods or medicines for regulating blood sugar. In conclusion, the enzymolysis product and the peptide fragment can be prepared into antidiabetic drugs or functional foods, and have the advantages of being natural, safe and efficient. The invention provides a new strategy for high-valued utilization of buffalo milk resources and treatment of type 2 diabetes.

The invention relates to the technical field of biology, in particular to an ACE inhibitory peptide, a preparation method and application, the ACE inhibitory peptide has the amino acid sequence of Trp-Pro-Phe (WPF) or Phe-Pro-Trp (FPW) or Phe-Gly-Trp (FGW) or Leu-Pro-Val-Pro-Ala-Phe-Asn (LPVPAFN) or Leu-Trp-Trp-Leu (LWWL), the ACE inhibitory peptide WPF, FPW, FGW, LPVPAFN and LWWL have outstanding antihypertensive activity, the IC50 values of the WPF, FPW, FGW, LPVPAFN and LWWL are 0.264 mg / mL, 0.800 mg / mL, 0.106 mg A variety of aquatic product peptide powder sources are separated and purified by an affinity ultrafiltration screening method, an ultrafiltrate component is selected for amino acid sequence identification, and a new amino acid sequence with ACE inhibitory activity is screened out; the ACE inhibitory peptides WFP, FPW, FGW, LPVPAFN and LWWL prepared by the invention have outstanding antihypertensive activity.

The present invention specifically relates to a method for extracting ACE inhibitory peptides from tilapia skin. Tilapia skin is a byproduct rich in collagen, and has important development significance as a raw material for screening ACE inhibitors. The present invention is designed to provide a method for extracting ACE inhibitors using tilapia skin as a raw material, comprising the following steps: defatting the tilapia skin and crushing it, adding acid to extract to obtain fish skin collagen crude protein, adding enzyme to the fish skin collagen crude protein for enzymolysis, and retaining the part of the enzymolysis product with a molecular weight less than 3kDa is the above-mentioned ACE inhibitory peptide; in particular, the above-mentioned enzyme is a product of Bacillus subtilis or Bacillus coagulans under gelatin-induced fermentation.

The invention discloses a tyrosinase inhibitory peptide from kelp as well as a preparation method and application of the tyrosinase inhibitory peptide. The preparation method comprises the following steps: pretreating kelp, fermenting the kelp by using lactobacillus plantarum, carrying out centrifugation, ultrafiltration and component identification on the obtained fermentation liquor to obtain the composition of kelp polypeptide, screening the tyrosinase inhibitory peptide through molecular docking, and finally carrying out solid-phase synthesis to obtain the tyrosinase inhibitory peptide prepared by the invention. The lactobacillus plantarum fermentation technology is simple and feasible, the production cost is low, equipment is easy to obtain, active ingredients in kelp can be released to the maximum extent, and the prepared polypeptide has the effect of inhibiting the activity of tyrosinase and can be used for developing a tyrosinase inhibitor.

The invention provides a spirulina-derived ACE (angiotensin converting enzyme) inhibitory peptide as well as a preparation method and application thereof, and belongs to the technical field of marine bioactive peptides. Spirulina phycobiliprotein is used for preparing the ACE inhibitory peptide of the spirulina source, five kinds of small molecule polypeptides including YATY, RYVTY, YVTY, KAYF and SPSWY are obtained through co-screening, the five kinds of polypeptides all have good ACE inhibitory activity, and the RYVTY activity is the highest. The spirulina-derived polypeptide prepared by the preparation method disclosed by the invention has high hydrolysis degree and high ACE inhibitory activity, can be applied to the fields of food, health care products, medicines and the like, and has a wide application prospect.

The invention discloses a TREM-1 inhibitory peptide nano-particle which is prepared by the following steps: by taking a dendritic polymer PAMAM as a carrier, coupling a TREM-1 inhibitory peptide with amino groups on the carrier by utilizing the characteristic of polyamino groups on the surface of the PAMAM, and coupling a brain-targeted peptide with the other part of amino groups on the carrier through MAL-PEG2000-NHS, so as to obtain the TREM-1 inhibitory peptide nano-particle. And modifying the residual amino groups on the carrier with PEG (Polyethylene Glycol) to obtain the nano-particles. The nanoparticles can relieve encephaledema, neuroinflammation injury and blood brain barrier damage caused by traumatic craniocerebral injury, improve cognitive impairment and long-term prognosis after trauma, and have a very high curative effect on clinical treatment of craniocerebral injury.

The invention relates to a preparation method and application of yolk polypeptide with ACE inhibitory activity, and the method comprises the following steps: Q1, adding degreased yolk powder into a proper amount of water, dissolving, and adjusting the pH value to 6-8; and Q2, adding alkaline protease or flavourzyme to carry out enzymolysis for 1.5-2.5 hours under the conditions that the temperature is 50-60 DEG C and the pH value is 7-8, and then carrying out enzyme deactivation to obtain the egg yolk hydrolysate. The ACE inhibitor with high activity is prepared by adopting step-by-step enzyme hydrolysis, five ACE inhibitory peptides (KFIPL, KFLPGY, KFLPTF, APTFGKL and KLPDMILY) with high activity are screened and identified by utilizing a bioinformatics method, and in order to solve the problem that the polypeptide is unstable after being sterilized in the functional beverage, CMC and GG are used as stabilizers, so that the utilization problem of the enzymolysis polypeptide in the functional beverage is solved.

The invention relates to the technical field of biologic stimulant preparation, and discloses a biologic stimulant mixing preparation two-stage control method, which comprises: adopting dissolved oxygen gradient and carbon source pulse cooperative control, linearly reducing the concentration of dissolved oxygen in a fermentation tank from an initial value at a specific rate, and injecting a carbon source at regular time; when the flora density and the quorum sensing signal molecule concentration reach specific threshold values, triggering stage switching; starting pressure-metabolism coupling control, increasing the pressure of the fermentation tank at a specific rate, and adding coenzyme Q10; the quorum sensing inhibitory peptide containing a specific core structure is synchronously released in the boosting process; after the pressure is stable, a real-time mapping relation between a microbial metabolism state and physical parameters is constructed in a thallus proliferation stage through a coupling mechanism of dissolved oxygen gradient control and quorum sensing signal monitoring, and the industrial problem that a traditional static threshold value cannot respond to pressure fluctuation of a fermentation tank to cause signal attenuation is solved.

The invention provides an angiotensin converting enzyme inhibitory peptide and application thereof. The amino acid sequence of the angiotensin converting enzyme inhibitory peptide is PVKP. The ACE inhibitory activity of the inhibitory peptide PVKP provided by the invention is obviously improved compared with that of the original inhibitory peptide LYPVK, and the IC50 value is reduced from 10.6 mu g / mL to 9.6 mu g / mL; the digestive enzyme stability of the inhibitory peptide PVKP provided by the invention and the digestive enzyme stability of the original inhibitory peptide LYPVK under the same concentration are improved. Molecular simulation docking verifies that the interaction force between the ACE inhibitory peptide PVKP and ACE is enhanced compared with that of an original inhibitory peptide LYPVK, and the interaction force between alkyl groups and the interaction between the alkyl groups and Zn < 2 + > of an ACE active center are increased. The intracellular antihypertensive activity of the ACE inhibitory peptide PVKP is further verified through cell experiments, and compared with the original inhibitory peptide LYPVK, the intracellular NO release content is increased, and the ET-1 content is reduced. The ACE inhibitory peptide PVKP is small in molecular weight and good in water solubility, and application of the ACE inhibitory peptide PVKP in development of products with the blood pressure lowering effect is facilitated.

The invention relates to the technical field of biochemistry, in particular to a specific affinity enrichment and preparation method of a torreya grandis protease hydrolysate ACE inhibitory peptide, which comprises the following steps: step 1, preparing and characterizing magnetic aminated Fe3O4 nanoparticles; step 2, preparing and characterizing the immobilized trypsin; 3, preparing and characterizing the immobilized ACE, and optimizing reaction conditions; step 4, determining the activity of the immobilized ACE; step 5, then preparing and specifically enriching the Chinese torreya antihypertensive peptide; step 6, then, carrying out molecular docking through AutoDock Vina; according to the method, genipin is adopted as a cross-linking agent, magnetic Fe3O4 nanoparticles with the ACE inhibitory peptide specific affinity recognition function are constructed, specific enrichment of the ACE inhibitory peptide from the torreya grandis cake protein hydrolysate is achieved, and specific separation is achieved.

The embodiment of the invention discloses a goat milk-derived ACE (angiotensin converting enzyme) inhibitory peptide monomer as well as a preparation method and application thereof, relates to the technical field of protein separation, and aims to improve a preparation source and preparation efficiency of a food-borne protein-derived ACE inhibitory peptide. The preparation method comprises the following steps: dissolving sheep milk casein in water, and carrying out heating treatment, enzymolysis treatment and freeze drying treatment to obtain a sheep milk source zymolyte; preparing the goat milk source zymolyte into a solution with the concentration of 145mg / mL-155mg / mL, passing through a 0.45 mu m filter membrane, and carrying out primary separation by adopting preparative high performance liquid chromatography to obtain a product Y; preparing the Y product into a solution with the concentration of 20 mg / mL-30 mg / mL, passing through a 0.45 mu m filter membrane, and carrying out secondary separation by adopting preparative high performance liquid chromatography to obtain a Y-X product; preparing the Y-X product into a solution with the concentration of 5mg / mL-15mg / mL, passing through a 0.45 mu m filter membrane, and carrying out re-separation preparation by using a C18 hydrophilic preparative column and preparative high performance liquid chromatography to obtain a product M; the product M is prepared into a solution with the concentration of 5 mg / mL-15 mg / mL, the solution passes through a 0.22-micron filter membrane, after re-separation preparation is conducted through RP-HPLC, rotary evaporation concentration treatment and freeze drying treatment are conducted, and a product F is obtained.

The invention discloses lactobacillus helveticus for producing DPP-IV (dipeptidyl peptidase-IV) inhibitory peptide and hypoglycemic goat milk and a preparation method thereof, goat milk is used as a raw material, and lactobacillus helveticus KD12 for producing the DPP-IV inhibitory peptide is used for fermenting the goat milk to obtain hypoglycemic lactobacillus fermented goat milk containing the DPP-IV inhibitory peptide. And drying the fermented goat milk to obtain the hypoglycemic lactic acid bacteria fermented goat milk powder containing the DPP-IV inhibitory peptide. Lactic acid bacteria of the hypoglycemic lactic acid bacteria fermented goat milk are inactivated to obtain hypoglycemic post-prebiotics goat milk, and the hypoglycemic post-prebiotics goat milk powder is obtained after the hypoglycemic post-prebiotics goat milk is concentrated and dried. The hypoglycemic goat dairy product provided by the invention has a relatively high DPP-IV inhibition rate, and can be used for inhibiting DPP-IV activity after consumers eat the hypoglycemic goat dairy product so as to reduce blood sugar and reduce the dosage of hypoglycemic drugs, so that side effects caused by the hypoglycemic drugs are reduced.

The invention belongs to the field of functional polypeptides, and discloses an elastinase inhibitory peptide and a preparation method thereof. The elastase inhibitory peptide comprises nine types of oligopeptides from crayfish, and the amino acid sequences of the oligopeptides are respectively GASGPAGPRGPVGVA, IDGF, GAAGPAGPRGPAGPA, SGPAGPA, GPAGPRGPVGVA, SGPAGPRGPVGVA, VGPQGASGPLGPA and IGPA. The invention further discloses a preparation method of the elastase inhibitory peptide. The elastinase inhibitory peptide disclosed by the invention can be chemically synthesized and can also be directionally prepared from fish gelatin enzymolysis products. The elastase inhibitory peptide disclosed by the invention has good binding force with elastase and has remarkable elastase inhibitory activity.

The invention belongs to the technical field of biological small molecule active peptides, and more specifically relates to a uric acid reducing active peptide, a preparation method and an application thereof. The uric acid reducing activity LQKW has remarkable XOD inhibitory activity, IC50 is 2.70 mg / mL, and the IC50 is superior to that of many known natural source XOD inhibitory peptides; good gastrointestinal digestion stability is shown, and the activity retention rate after in-vitro simulated gastrointestinal digestion is (61.84 + / -0.82)%. According to the invention, a specific binding mechanism of uric acid reduction activity and XOD active sites (Ile648, Phe649 and the like) is clarified through molecular docking, and a basis is provided for rational design based on a structure. According to the invention, the method for efficiently preparing the active peptide fragment from the white spirit vinasse is established, and the high-valued utilization of the wine brewing byproducts is realized. The uric acid reducing activity LQKW provided by the invention can be prepared through solid-phase synthesis, the process is mature, the quality is controllable, and a foundation is laid for industrialization. In addition, as the XOD inhibitor of a natural source, the uric acid reducing activity LQKW has good safety.

The invention discloses a composition with effects of losing weight and reducing blood fat. Every 100g of the composition comprises the following components and contents: (1) 10-30mg of adiponectin functional fragments; (2) 5 to 15 mg of PCSK9 inhibitory peptide; (3) 1-5 g of a radix puerariae extract; (4) 1-3 g of garcinia cambogia extract; (5) 0.5-2 g of a green coffee bean extract; (6) 1 to 3g of microencapsulated fish oil; (7) 0.5 to 1g of chitosan; and 5 to 10 g of erythritol. Through the synergistic effect of various bioactive components, the composition can effectively reduce fat accumulation and reduce the blood fat level, and meanwhile has good taste and use convenience. The composition disclosed by the invention provides an innovative solution for losing weight and reducing blood fat, and has potential clinical and commercial application values.

The invention belongs to the technical field of biology, and particularly relates to a colipase inhibitory peptide and application thereof. The colipase inhibitory peptide has colipase inhibitory activity, can significantly reduce fat absorption by inhibiting the activity of colipase, achieves the effects of losing weight and reducing blood fat, is safe and free of toxic and side effects, has good stability and low blood absorptivity, and is beneficial for polypeptide to better inhibit the colipase to play a role in digestive tracts.

The invention discloses a scallop skirt ACE inhibitory peptide activity method and system based on deep learning, and relates to the technical field of bioengineering.The scallop skirt ACE inhibitory peptide activity method comprises the steps that a comprehensive data set is obtained based on simulated in-vivo test data and peptide level feature data of different peptides, key features are screened, and a training set and a test set are divided; initializing a random forest model, an SVM model and a logistic regression model, performing independent training by using the training set, and determining an optimal prediction model of the peptide antihypertensive activity based on a prediction result of the test set; extracting importance data of key features based on the optimal prediction model for the antihypertensive activity of the peptide, sorting the importance data, and visually analyzing the antihypertensive activity features, feature importance sorting and model performance of different peptides; and all key results in the analysis process are integrated and systematically stored. According to the method, normal form reference with prediction accuracy and mechanism depth can be provided for clinical transformation of marine bioactive peptides, and AI-driven novel peptide drug research and development are promoted to enter a new stage.

The invention belongs to the field of biological pharmacy, and relates to an alpha-amylase inhibitory peptide and application thereof. Specifically, the provided unreported peptide fragment LDKFLWT can effectively inhibit the activity of alpha-amylase, and animal experiments prove that the newly designed polypeptide has the effects of reducing blood sugar, reducing blood fat, improving insulin resistance and the like through polypeptide intervention; compared with a traditional hypoglycemic drug, the alpha-amylase inhibitory peptide disclosed by the invention has remarkable safety.

The present invention relates to the field of protein engineering, and specifically relates to a Morchella esculenta peptide and the use thereof. By means of comprehensively applying bioinformatic methods such as virtual enzymolysis, activity prediction, physicochemical property and safety evaluation, and molecular docking, one Morchella esculenta peptide having the potential effects of "inhibiting oxidation + skin whitening" is screened from Morchella esculenta, which peptide has a sequence of WWVCAK. In-vitro chemical experiments verify that WWVCAK is the most effective antioxidant and tyrosinase-inhibitory peptide. Therefore, WWVCAK can exert the effects of inhibting oxidation and skin whitening via multiple targets, multiple functions and multiple pathways. WWVCAK is expected to be developed and used in cosmetics as a functional skin-care ingredient with the twin effects of "inhibiting oxidation + skin whitening".

The invention discloses a mulberry leaf antihypertensive active peptide as well as a preparation method and application thereof. According to the method, mulberry leaves are used as raw materials to prepare mulberry leaf albumin, enzymolysis parameters of enzymolysis time, pH, enzyme-substrate ratio and substrate concentration are optimized through a single factor experiment and an orthogonal experiment, and optimal enzymolysis conditions for preparing the ACE inhibitory peptide crude product are provided; the high-activity ACE inhibitory peptide is identified through further purification, polypeptide sequence determination and virtual screening, the ACE inhibitory peptide has extremely high solubility and good ACE inhibitory activity, and the IC50 values of the two peptides VPSCFDLTGK and RLPDFHGL with the highest activity are 8.23 [mu] mol / L (8.765 [mu] g / mL) and 23.01 [mu] mol / L (23.58 [mu] g / mL) respectively. The active peptide can be used as an angiotensin converting enzyme inhibitory peptide, and achieves the purpose of reducing blood pressure by inhibiting ACE activity.

A novel PACE4 inhibitor and use thereof in anti-osteoarthritis. A novel PACE4 inhibitory peptide is designed and synthesized, which can effectively inhibit the expression of extracellular PACE4 without affecting normal cells, and is stable in joints and unstable in plasma, so that the PACE4 inhibitory peptide has excellent safety and can be effectively used in the prevention and treatment of OA.

This invention discloses the XO-inhibiting peptide GDEY and its applications, belonging to the field of bioactive peptide technology. The amino acid sequence of the XO-inhibiting peptide GDEY is shown in SEQ ID NO.2. The invention also discloses the application of the XO-inhibiting peptide GDEY in the preparation of xanthine oxidase inhibitors and in the preparation of drugs with the effect of inhibiting uric acid levels. This invention used molecular docking and BLAST+ software to virtually screen 15 potential XO-inhibiting peptides from the complete protein sequence of Litopenaeus vannamei. High-performance liquid chromatography (HPLC) was used to determine the XO-inhibiting activity, and the results showed that 7 small molecule peptides exhibited significant XO-inhibiting activity, possessing potential value in preventing hyperuricemia.

The application discloses a polypeptide-based anti-fouling electrochemical sensor and a construction method and application thereof. In the application, cysteine is used as an anchoring end, an alpha-helix structure is formed by inserting polyproline to give a supporting effect to the whole peptide, then angiotensin converting enzyme inhibitory peptide (KSRE) and alpha-glucosidase inhibitory peptide (EKDER) are used as branches to prepare the anti-fouling polypeptide. The anti-fouling polypeptide has a better anti-fouling effect than other anti-fouling polypeptides, and the working electrode is modified by the anti-fouling polypeptide to prepare an anti-fouling electrochemical aptamer sensor for detecting AFB1, so that the anti-pollutant interference effect of the sensor can be greatly improved, the accuracy and sensitivity of AFB1 detection can be improved, and the anti-fouling electrochemical aptamer sensor has a wide application prospect.

The application discloses a Vibrio parahaemolyticus quorum sensing inhibiting peptide and application thereof, and belongs to the field of bioactive peptides. The inhibiting peptide comprises the following amino acid sequence: Ser-Phe; the application further discloses application of the quorum sensing inhibiting peptide in inhibiting Vibrio parahaemolyticus or preparing antibacterial drugs for inhibiting Vibrio parahaemolyticus. The application adopts a molecular docking technology to screen an active peptide having an inhibiting effect on a Vibrio parahaemolyticus LuxS / AI-2 quorum sensing system, ADMET property prediction is carried out on a peptide segment with better binding force, and finally, a bioactive peptide SF stably combined with LuxP, LuxQ and LuxS is obtained; the dipeptide has good in-vitro inhibiting activity on the Vibrio parahaemolyticus LuxS / AI-2 quorum sensing, and has no cytotoxicity. The dipeptide obtained by the application can be used for guiding development of a new type of antibacterial preparation applied to food, medicine and agriculture and other fields, and has great significance for human health and agricultural development.

The present disclosure relates to improved GLP-1 receptor agonist polypeptides and molecules comprising these improved GLP-1 receptor agonist polypeptides, such as molecules comprising one or more GLP-1 receptor agonist polypeptides conjugated to an anti- gastric inhibitory peptide receptor (GIPR) antibody. The present disclosure is also directed to the use of these improved GLP-1 receptor agonist polypeptides and conjugate molecules comprising these polypeptides for treating or preventing obesity, an obesity related condition, type 2 diabetes, and / or a type 2 diabetes related condition.

The invention discloses goat milk with hypoglycemic activity and a preparation method thereof, and belongs to the technical field of enzyme engineering. The goat milk is used as a raw material, enzymolysis goat milk with alpha-G inhibitory activity is obtained through compound protease hydrolysis, it is found that the enzymolysis goat milk has hypoglycemic activity, and the goat milk powder with the hypoglycemic activity is further prepared through spray drying. The alpha-G inhibitory peptides in the enzymolysis goat milk are separated and identified, 20 alpha-G inhibitory peptides are found from components with the highest alpha-G inhibition rate, the molecular weight of the alpha-G inhibitory peptides is 377-962 Da, and the alpha-G inhibitory peptides are mainly derived from beta-casein, alpha S1-casein, alpha S2-casein, kappa-casein, beta-lactoglobulin, lactoglobulin and osteopontin of the goat milk. The alpha-G inhibitory peptide is prepared by hydrolyzing the goat milk through the compound enzyme, the amino acid sequence of the alpha-G inhibitory peptide is separated and identified, the goat milk with hypoglycemic activity is developed, and theoretical basis and technical support are provided for subsequent development of hypoglycemic dairy products.